8-K: Galectin Therapeutics' Belapectin Shows Significant Efficacy in Preventing Varices in MASH Cirrhosis Patients

Galectin Therapeutics Inc. announced positive 18-month results from its NAVIGATE Phase 2b trial, demonstrating that Belapectin significantly reduced the incidence of new esophageal varices in patients with MASH cirrhosis and portal hypertension.

Summary

• Galectin Therapeutics (GALT) presented 18-month results from its NAVIGATE Phase 2b trial for Belapectin in patients with MASH cirrhosis and portal hypertension.
• The 2 mg/kg dose of Belapectin significantly reduced the incidence of new esophageal varices in the per-protocol population (p=0.04) and showed a significant effect on the composite primary endpoint in the ITT population (p=0.048).
• Belapectin demonstrated a favorable safety profile, with adverse events, serious adverse events, and discontinuation rates comparable to placebo.
• There were no drug-related serious adverse events or adjudicated Drug-Induced Liver Injury (DILI) events reported in the entire trial.
• MASH cirrhosis with portal hypertension represents a significant unmet medical need, as there are currently no FDA-approved therapies to reverse fibrosis or portal hypertension in this condition.
• The addressable market in the U.S. includes approximately 3.3 million patients with MASH cirrhosis and portal hypertension, with an estimated 1.7 million having compensated cirrhosis and portal hypertension without varices in 2024.
• Third-party market opportunity assessment suggests potential peak Belapectin sales in the U.S. could reach $18 billion.

Sentiment

Score: 8

Explanation: The document presents highly positive clinical trial results for Belapectin, addressing a significant unmet medical need with a favorable safety profile and substantial market potential, indicating strong progress and future prospects for the company.

Positives

• Belapectin 2 mg/kg significantly reduced the incidence of new esophageal varices at 18 months in patients with MASH cirrhosis and portal hypertension (p=0.04 in completers, p=0.048 for composite primary endpoint in ITT population).
• The drug exhibited a favorable safety profile, with adverse events, serious adverse events, and discontinuation rates similar to placebo.
• No drug-related serious adverse events or Adjudicated Drug-Induced Liver Injury (DILI) events were reported during the trial.
• Categorical changes in Liver Stiffness Measure (LSM) mirrored the lower incidence of new varices in the 2 mg cohort compared to placebo.
• These findings validate prior favorable observations from the GT-026 trial, reinforcing Belapectin's potential.
• Belapectin has the potential to be a firstand best-in-class therapy for MASH cirrhosis, addressing a critical unmet medical need.
• The market opportunity for Belapectin is substantial, with estimated peak sales of $18 billion in the U.S. for MASH cirrhosis patients.

Negatives

• The 4 mg/kg dose of Belapectin did not show the same statistical significance in reducing new varices as the 2 mg/kg dose.

Risks

• Forward-looking statements contained in the report and presentation are based on current expectations and are not guarantees of future performance; actual events or results may differ materially.
• There are currently no FDA-approved therapies to reverse fibrosis in MASH cirrhosis, indicating the inherent challenges and high bar for drug development in this disease area.
• MASH is considered to be underdiagnosed, which could impact patient identification and market penetration.
• A significant portion of patients listed for liver transplant (30%) die while waiting, highlighting the severe progression risk of the disease if not effectively treated.

Future Outlook

Belapectin is positioned to address a critical unmet medical need in patients with MASH cirrhosis and portal hypertension, with the potential to be a firstand best-in-class therapy. The positive Phase 2b results suggest a strong path forward for further clinical development and potential market entry, targeting a significant patient population and substantial market opportunity.

Management Comments

• Joel Lewis (CEO & President) and Khurram Jamil, M.D. (CMO) presented the clinical data and company overview, indicating management's confidence and endorsement of the positive trial results and strategic direction.

Industry Context

Metabolic dysfunction-associated steatohepatitis (MASH), formerly NASH, affects 3-5% of the global population and is a leading cause of liver disease progression. There are currently no FDA-approved therapies to reverse fibrosis in MASH cirrhosis or to reverse portal hypertension once it develops. While Madrigal's Rezdiffra was recently approved for F2/3 MASH patients, Belapectin targets the more advanced stage of MASH cirrhosis with portal hypertension, where treatment options are severely limited. This positions Belapectin to fill a significant therapeutic gap in a high-risk, underserved patient population.

Comparison to Industry Standards

• Currently, no FDA-approved therapies exist to reverse fibrosis in MASH cirrhosis, highlighting Belapectin's potential to be a pioneering treatment.
• There are no approved therapies specifically designed to reverse portal hypertension once it develops in MASH Cirrhosis, positioning Belapectin as a potential first-in-class solution for this critical complication.
• Unlike Madrigal's Rezdiffra, which was recently approved for F2/3 MASH patients, Belapectin targets the more advanced MASH cirrhosis population, addressing a distinct and more severe stage of the disease where late-stage options are limited.

Stakeholder Impact

• Shareholders: Positive clinical trial results and a large market opportunity could lead to increased shareholder value and investor confidence.
• Patients: Offers a potential novel therapeutic option to prevent severe complications like esophageal varices and liver decompensation in MASH cirrhosis, addressing a critical unmet medical need.
• Healthcare Providers: Provides a promising new treatment tool for managing patients with advanced MASH, where current options are limited.

Next Steps

• Further regulatory discussions and potential advancement to Phase 3 clinical trials are implied based on the positive Phase 2b results.
• Continued engagement with the medical community through presentations and publications to disseminate trial findings.

Key Dates

Recommendation

Keywords

Belapectin, MASH, NASH, cirrhosis, portal hypertension, Galectin-3 inhibitor, clinical trial, NAVIGATE, esophageal varices, liver fibrosis, biotechnology, pharmaceutical, drug development, GALT